The recent decision by partner BioNTech (BNTX) to give up on co-development of acasunlimab may also be considered as bad news, but if the candidate delivers good data in a pivotal trial ...

If this EUA application is authorised, children 6 months to under 5 years of age would receive a primary series consisting of two 3-µg doses of the original Pfizer/BioNTech COVID-19 Vaccine ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Karim Beguir is the co-founder and CEO of InstaDeep, a Tunisian startup that was acquired for $682 million by BioNTech.

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

The Pfizer-BioNTech and Moderna vaccines rely on the ... prevent COVID-19," Dr. Peter Marks from the FDA told NPR in an interview. "But if we can prevent people from getting serious cases that ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...

Healthcare & Pharmaceuticalscategory US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug June 17, 2024 Reuters, the news and media division of Thomson Reuters, ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

WASHINGTON — Vice President Kamala Harris will give her first interview as the Democrats’ presidential nominee Thursday to CNN — in a high-stakes test of her ability to defend her record and ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...